FCM Investments TX Has $687,000 Position in Pfizer Inc. (PFE)
FCM Investments TX held its position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 19,517 shares of the biopharmaceutical company’s stock at the end of the second quarter. FCM Investments TX’s holdings in Pfizer were worth $687,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently bought and sold shares of PFE. Bridges Investment Management Inc. boosted its position in shares of Pfizer by 1.1% in the first quarter. Bridges Investment Management Inc. now owns 28,220 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 313 shares during the last quarter. PM CAPITAL Ltd purchased a new position in shares of Pfizer during the first quarter valued at $39,264,000. Murphy Pohlad Asset Management LLC boosted its position in shares of Pfizer by 12.8% in the first quarter. Murphy Pohlad Asset Management LLC now owns 59,141 shares of the biopharmaceutical company’s stock valued at $1,752,000 after buying an additional 6,710 shares during the last quarter. Stokes & Hubbell Capital Management LLC boosted its position in shares of Pfizer by 93.6% in the first quarter. Stokes & Hubbell Capital Management LLC now owns 42,534 shares of the biopharmaceutical company’s stock valued at $1,261,000 after buying an additional 20,567 shares during the last quarter. Finally, Raymond James Trust N.A. boosted its position in shares of Pfizer by 0.4% in the first quarter. Raymond James Trust N.A. now owns 443,037 shares of the biopharmaceutical company’s stock valued at $13,132,000 after buying an additional 1,709 shares during the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.31% during mid-day trading on Friday, reaching $32.66. The company had a trading volume of 15,569,339 shares. The firm has a market capitalization of $198.10 billion, a P/E ratio of 28.95 and a beta of 0.86. The stock’s 50-day moving average is $34.02 and its 200 day moving average is $34.27. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the previous year, the firm posted $0.56 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.67%. Pfizer’s dividend payout ratio is currently 95.24%.
A number of research analysts have commented on the stock. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 target price on the stock in a research report on Tuesday, August 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $54.00 target price on shares of Pfizer in a research report on Monday, June 27th. BMO Capital Markets reaffirmed a “buy” rating and issued a $40.00 target price on shares of Pfizer in a research report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Eleven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.